West Fraser Reports Goodwill Impairment for Q4-March 2024-www.financetom.com

West Fraser Reports Goodwill Impairment for Q4

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

West Fraser Reports Goodwill Impairment for Q4

Mar 11, 2026 12:06 AM

05:51 PM EST, 01/08/2026 (MT Newswires) -- West Fraser Timber ( WFG ) said late Thursday it will record an impairment of its Lumber segment goodwill in Q4 of 2025 due to persistently challenging economic conditions.

The company said it expects to record about $409 million non-cash impairment of goodwill due to the downcycle.

The firm also said it expects capital expenditures of $300 million to $350 million for 2026.

Previous page： Basel Medical Group Reiterates in Regulatory Filing Underlying Business Strength Following Continued Volatility in Shares Next page： Autoliv raises dividend, reiterates 2025 guidance

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Basel Medical Group Reiterates in Regulatory Filing Underlying Business Strength Following Continued Volatility in Shares

Jun 4, 2025

05:46 AM EDT, 06/04/2025 (MT Newswires) -- Basel Medical Group's ( BMGL ) shares were trading down more than 12% in premarket activity Wednesday, heading for another day of volatile price moves despite the company making statements regarding its fundamental underlying strength. On Tuesday, the company issued a Form 6-K regulatory filing, drawing attention to a press statement from May...

Autoliv raises dividend, reiterates 2025 guidance

Jun 4, 2025

STOCKHOLM, June 4 (Reuters) - Swedish Autoliv , the world's biggest maker of airbags and seatbelts, on Wednesday reiterated its outlook for 2025 and said it would raise its dividend for the third quarter to $0.85 per share from $0.70 in the second quarter. Autoliv ( ALV ) said in a statement it would tweak its target leverage ratio to...

Sagimet Biosciences Says Acne Vulgaris Treatment Meets Phase 3 Trial Primary, Secondary Endpoints

Jun 4, 2025

05:43 AM EDT, 06/04/2025 (MT Newswires) -- Sagimet Biosciences ( SGMT ) said Wednesday that denifanstat met all primary and secondary endpoints in a phase 3 clinical trial to treat moderate to severe acne vulgaris. The trial was conducted by the company's license partner Ascletis Bioscience in China. Denifanstat was generally well-tolerated, the company said. After 12 weeks of once-daily...

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...